Fenofibrate: Detailed Dossier for Research Use

Executive Summary: Fenofibrate is a specific peroxisome proliferator-activated receptor alpha (PPARα) agonist with established efficacy in activating lipid metabolism pathways in vitro and in vivo (product details). It robustly induces liver enlargement in both adult and aging mouse models by activating PPARα and the yes-associated protein (YAP) signaling pathway, according to recent peer-reviewed studies (Chemico-Biological Interactions). The compound exhibits dose- and time-dependent cytotoxicity in cancer cell lines, supporting its role in cancer biology research. Fenofibrate’s effects occur independently of age, providing reproducibility across experimental cohorts. APExBIO supplies Fenofibrate (SKU: B1943) with detailed solubility and handling parameters for laboratory workflows.

Biological Rationale

Fenofibrate is a synthetic ligand for PPARα, a nuclear receptor central to the regulation of lipid metabolism, fatty acid β-oxidation, and energy homeostasis. PPARα is predominantly expressed in the liver, heart, kidney, and intestine. Activation of PPARα has been shown to enhance hepatic fatty acid uptake and catabolism, making PPARα agonists such as Fenofibrate valuable tools in metabolic research (reference study). In recent years, the link between PPARα activation and the YAP signaling pathway has emerged as a critical axis for regulating liver growth and regeneration.

Mechanism of Action of Fenofibrate

Fenofibrate exerts its biological effects as a potent PPARα agonist, with EC50 values of 18 μM (mouse) and 30 μM (human) as determined in cell-based assays (APExBIO datasheet). Upon binding to PPARα, Fenofibrate triggers the transcription of genes involved in fatty acid oxidation, lipid transport, and energy metabolism. Concurrently, Fenofibrate promotes YAP nuclear translocation in hepatocytes, activating downstream targets that regulate organ size and cell proliferation (Chemico-Biological Interactions). This dual mechanism underscores Fenofibrate’s utility in studies of both metabolic and proliferative liver responses.

Evidence & Benchmarks

• Fenofibrate induces significant liver enlargement (hypertrophy and hyperplasia) in both adult and aging mouse models, with effects independent of age (DOI).
• The compound activates the PPARα-YAP signaling pathway, increasing expression of proliferation-related proteins and nuclear YAP localization in hepatocytes (DOI).
• Fenofibrate demonstrates dose- and time-dependent cytotoxicity in MCF-7 (breast) and Panc-1 (pancreatic) cancer cell lines, with IC50 values decreasing over 24, 48, and 72 hours (product information).
• In vivo, Fenofibrate reduces tumor weight and volume in mice bearing Ehrlich ascites carcinoma, without adverse effects on heart weight; notable increases in relative liver weight and decreases in body weight are observed (product information).
• Solubility benchmarks: Fenofibrate is insoluble in water, but dissolves in DMSO (≥12.75 mg/mL at 37°C) and ethanol (≥18.57 mg/mL at 37°C), facilitating preparation of 10 mM stock solutions for cell culture and in vivo dosing (APExBIO).

For detailed mechanistic comparison, see also "Fenofibrate Activates PPARα-YAP Pathway to Enlarge Aging Mouse Liver", which confirms the independence of Fenofibrate’s effects from age; the current article expands benchmark data and solubility parameters for experimental planning.

Applications, Limits & Misconceptions

Fenofibrate is primarily used in research models to dissect pathways involved in lipid metabolism, hepatocyte proliferation, and cancer biology. It is also instrumental in probing the relationship between PPARα and YAP signaling in organ size regulation. While Fenofibrate’s effects on liver enlargement and metabolic gene induction are robust, the following caveats apply:

Common Pitfalls or Misconceptions

• Fenofibrate is not suitable for diagnostic or therapeutic use in humans or animals; it is strictly for scientific research (APExBIO).
• Liver enlargement induced by Fenofibrate in mouse models is non-adverse and does not equate to hepatotoxicity or pathological hepatomegaly (DOI).
• Fenofibrate’s activation of the YAP pathway is limited to liver and does not directly extrapolate to other organs without supporting evidence.
• Solubility in DMSO requires warming to 37°C or ultrasonic agitation; incomplete dissolution may compromise dosing accuracy.
• Long-term storage of solutions is not recommended due to compound instability; freshly prepared solutions are preferred.

Workflow Integration & Parameters

For reliable laboratory use, Fenofibrate (B1943) from APExBIO is supplied as a solid compound. Key parameters include:

Protocol Parameters

• Stock Solution Preparation: Dissolve Fenofibrate in DMSO (≥12.75 mg/mL) or ethanol (≥18.57 mg/mL) at 37°C; use ultrasonic shaking for rapid dissolution.
• Cell Culture Assays: Prepare working concentrations by diluting 10 mM DMSO stock into culture medium; ensure final DMSO ≤0.1% (v/v) in wells.
• In Vivo Studies: Formulations may require vehicle compatibility testing; monitor animal body and organ weights as endpoints.
• Storage: Store solid at -20°C; avoid repeated freeze-thaw cycles. Solutions should be freshly made and are not suitable for long-term storage.
• Shipping: Product is shipped with blue ice to preserve stability during transit.

Conclusion & Outlook

Fenofibrate’s well-characterized action on the PPARα-YAP axis makes it a valuable tool for dissecting lipid metabolism and proliferative signaling in both adult and aging research models (recent study). Its robust, age-independent induction of liver enlargement offers new insight into organ size regulation and model selection for metabolic and cancer biology research. The product’s defined solubility and handling parameters, as specified by APExBIO, support reproducible workflows. Future research may further clarify the nuanced interplay between metabolic and proliferative pathways in the context of aging, but current evidence supports Fenofibrate’s use primarily within hepatic and cancer domains.